HEMO-

Main information

  • Trade name:
  • HEMO-15 VITAMIN-AMINO ACID INJECTION
  • Pharmaceutical form:
  • PARENTERAL LIQUID/SOLUTION/SUSPENSION
  • Units in package:
  • 100mL
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • HEMO-15 VITAMIN-AMINO ACID INJECTION
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • HORSE | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT STUD | MARE | PACER | POL
  • Therapeutic area:
  • vitamins,minerals,etc.
  • Therapeutic indications:
  • NOT APPLICABLE (VET)
  • Product summary:
  • Contains ammonium ferric citrate 15mg/mL, vitamins, minerals, lipotropes and amino acids. Designed as a supplementary source of these nutritional substances in horses.For use only by or under the direction of a registered veterinary surgeon.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 35748/105171
  • Authorization date:
  • 06-04-2016
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

VETOQUINOL AUSTRALIA PTY LTD

HEMO-15 VITAMIN-AMINO ACID INJECTION

35748/105171

Company Name:

Product Name:

APVMA Approval No:

Label Name:

HEMO-15 VITAMIN-AMINO ACID INJECTION

Signal Headings:

FOR ANIMAL TREATMENT ONLY

Constituent

Statements:

CONTENTS: Each mL contains:

Ammonium Ferric Citrate - 15 mg

Nicotinamide -100 mg

D-Panthenol - 15 mg

Choline Chloride - 10 mg

Inositol - 10 mg

Pyridoxine Hydrochloride - 10 mg

Riboflavin (Sodium Phosphate) - 10 mg

Cyanocobalamin (B12) - 150 µg

Biotin - 10 µg

Cobalt Gluconate - 0.7 mg

Copper Gluconate - 0.2 mg

Glycine - 20 mg

L-Lysine Hydrochloride - 20 mg

DL-Methionine - 20 mg

Preservative

Benzyl alcohol - 20 mg

Claims:

HEMO-15® contains Ammonium Ferric Citrate 15 mg/mL, Vitamins, Minerals, Lipotropes

and Amino Acids.

HEMO-15® is designed as a supplementary source of these nutritional substances in

horses.

Hemo-15 is a potent supplemental source of those nutritional factors which may be lacking

from the daily diet of race horses. Recent research indicates that environmental factors

influencing the vitamin-mineral-protein content of such feeds as hay, whole grain, and oral

supplements provide a rationale for the use of Hemo-15.

Net Contents:

100mL

Directions for Use:

RLP

APPROVED

Restraints:

Contraindications:

Excessive copper is toxic. This product is contraindicated for use unless copper and cobalt

deficiency is confirmed.

Precautions:

Minerals such as copper, cobalt, selenium, iron, manganese and molybdenum compete

with each other for metabolically important processes in the animal. Users should seek

veterinary advice before treatment.

Side Effects:

Dosage and

Administration:

Discard unused portion within 30 days of first broaching vial.

The dosage for horses is 1mL per 50kg of body weight by intramuscular or intravenous

injection.

10mL Hemo-15® may be added to any I.V. Solution. This will ensure that veterinary amino-

acid solutions are increased in potency to acceptable therapeutic levels. Also, the vitamins

and minerals will provide for increased production in red cells and haemoglobin.

Hemo-15® may also be administered by intramuscular or intravenous injection.

General Directions:

FOR USE ONLY BY OR UNDER the direction of a registered veterinary surgeon.

Hemo-15® may be used in several ways:

1. As an additive for all intravenous fluids such as amino-acid-vitamin mixtures,

electrolytes, and dextrose.

2. Following a race to replace essential substances lost through the stresses of racing.

3. As a pre-activity injection with an energy producing potential.

Withholding

Periods:

WITHHOLDING PERIODS: MEAT Zero (0) days.

Trade Advice:

Safety Directions:

May irritate the eyes and skin. Avoid contact with eyes and skin. Wash hands after use.

First Aid

Instructions:

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia

131126.

First Aid Warnings:

Additional User

Safety:

Environmental

Statements:

Disposal:

Dispose of empty container by wrapping with paper and putting in garbage. Discarded

needles/sharps should immediately be placed in a designated and appropriately labelled

‘sharps’ container.

Storage:

Store below 25ºC (Air conditioning).

16-1-2019

Safety and efficacy of 3‐phytase FSF10000 as a feed additive for chickens for fattening or reared for laying, laying hens and minor poultry species

Safety and efficacy of 3‐phytase FSF10000 as a feed additive for chickens for fattening or reared for laying, laying hens and minor poultry species

Published on: Tue, 15 Jan 2019 The additive 3‐phytase FSF10000 is a solid product that contains a 3‐phytase produced by a genetically modified strain of Komagataella phaffii. A liquid formulation of the additive has been previously assessed by the EFSA Panel on Additives and Products of Substances used in Animal Feed (FEEDAP) and is currently authorised as a feed additive for poultry species. The applicant requested for the use of this new formulation of the additive in chickens for fattening or reared ...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-1-2019

Safety assessment of the substance, montmorillonite clay modified with hexadecyltrimethylammonium bromide, for use in food contact materials

Safety assessment of the substance, montmorillonite clay modified with hexadecyltrimethylammonium bromide, for use in food contact materials

Published on: Mon, 14 Jan 2019 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of montmorillonite clay modified with hexadecyltrimethylammonium bromide (HDTA) when used as an additive at up to ■■■■■ in polylactic acid (PLA) bottles intended for contact with water for long‐term storage at ambient temperature or below. The modified clay, which 90% w/w of the particles have a dimension of 33.1 μm or less and the average size is 9 μm, has a layered structure w...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

3-1-2012

Danish Pharmacovigilance Update, 15 December 2011

Danish Pharmacovigilance Update, 15 December 2011

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.

Danish Medicines Agency

15-5-2018

Effentora (Teva B.V.)

Effentora (Teva B.V.)

Effentora (Active substance: fentanyl citrate) - PSUSA - Modification - Commission Decision (2018)3013 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/1369/201704

Europe -DG Health and Food Safety